Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

China healthcare investment booms on virus-related spending bets

Stock MarketsMay 14, 2020 07:05PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.

By Julie Zhu and Kane Wu

HONG KONG (Reuters) - China's healthcare and biotech firms are capitalising on a surge of interest in the sector due to the coronavirus pandemic by raising a record $6.8 billion in fresh equity-linked transactions this year.

While healthcare and related sectors have long been popular, with investors betting that China's ageing population and growing middle class would boost spending, the virus has raised expectations that Beijing will funnel even more funds into them.

"Because of the epidemic outbreak, the biotech, healthcare industry has been valued more by everyone. People realise that no matter what the economy looks like, patients always need to see the doctor," said Xia Yu, co-founder and CEO of Chinese biotech firm Akeso Inc.

China's healthcare expenditure accounted for just 6.6% of its GDP in 2018, compared with 17.7% in the United States, according to official data from the two countries.

"After the virus outbreak, government and society will greatly increase spending on healthcare systems, which will benefit the industry," said Andy Lin, founding partner of Chinese private equity firm Loyal Valley Capital.

Loyal Valley has been looking into investment in vaccine- and testing-related companies and encouraged portfolio firms like Shanghai Junshi Biosciences to expand into businesses related to tackling the coronavirus, he said.

Chinese biotech and healthcare firms have raised $2.1 billion from IPOs in mainland China, Hong Kong and the United States this year, nearly double the rate this time last year, according to Refinitiv data.

Healthcare-related companies have been a driving force in Hong Kong in particular this year, accounting for 30% of the total $2.78 billion raised via IPOs in the city, Refinitiv data showed.

"It is really the scarcity value. Healthcare right now is probably the most active sector (in the capital markets)," said Cathy Zhang, a managing director at Morgan Stanley (NYSE:MS) and head of healthcare for Global Capital Markets in Asia.

She also attributed investors' confidence to strong market performance of many biotech firms.

HEAVILY OVERSUBSCRIBED

An index of Hong Kong-listed biotechs has gained 14% so far this year while the benchmark Hang Seng Index has fallen by about 15%.

Akeso, which focuses on oncology and immunology, raised $330 million last month in the city's largest IPO this year. Other significant transactions include InnoCare Pharma's $288 million IPO in March and medical devices maker Peijia Medical's $302 million deal this month.

Both Akeso and Peijia's offerings were heavily oversubscribed by retail and institutional investors, with the retail tranche being over 600 times and 1,000 times covered, respectively, according to public filings and people close to the deals.

As well as IPOs, investment banks including JPMorgan (NYSE:JPM) and Morgan Stanley are looking to already-listed groups to raise further funds via follow-on share sales and convertible bonds.

"For (pre-revenue) biotech companies, it is very important that you are able to continuously raise money after the IPO... The sector's stocks have done quite well, so obviously biotech companies want to take advantage of the share price to continue to raise capital," said Morgan Stanley's Zhang.

Already-listed firms have raised $3.3 billion in follow-on share sales and $1.3 billion from convertible bonds this year, against $1 billion and $712 million, respectively, by this time last year, showed Refinitiv data.

Some investors and bankers cautioned that despite the rising interest in the sector, many firms might still have to adjust valuations and maintain business growth as the overall economic and market conditions have turned challenging since the virus outbreak.

"It is actually a testing ground for their abilities," said Nisa Leung, managing partner and leader of healthcare sector at China-based Qiming Venture Partners.

China healthcare investment booms on virus-related spending bets
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Buzzy Jefferson
Buzzy Jefferson May 14, 2020 7:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I wonder where socialist Reuters gets their numbers.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email